Non-alcoholic fatty liver disease: current therapeutic prospects
Non-alcoholic fatty disease (NAFLD) is one of the most common diseases in hepatology, which is caused by a high risk of its progression with the development of non-alcoholic steatohepatitis, liver fibrosis and hepatocellular carcinoma. In spite of the fact that the specific therapy of NAFLD is not currently developed, it should be combined and aimed at correcting all the links involved in the pathological process. The main goal is to prevent the progression of the disease: reducing the severity of steatosis, preventing the progression of the disease in steatohepatitis, fibrosis and cirrhosis, as well as reduce the risk of cardiovascular complications.